China-based biopharmaceutical company Antengene has secured around $97 million funding in its Series C funding round, the media reported.
Antengene is hematology and oncology-focused biopharmaceutical company with integrated drug discovery, clinical development, manufacturing and commercialisation anchored in the Asia Pacific regions and with a global layout.
The funding round for Antengene was led by Fidelity Management & Research Company. Other investors who also participated in the funding round include GL Ventures, GIC, Qiming Venture Partners, and Boyu Capital.
Reportedly, Antengene will use the funds to use the funds for the continuing clinical development of its pipeline of hematology and oncology therapies, expanding in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets.
Jay Mei, Founder, Chairman and chief executive of Antengene told the media, “We appreciate the recognition and trust from these prestigious investment institutions. This round of financing has drawn support from among the world’s largest asset managers, top-tier healthcare investors widely recognized in the capital markets, and strong continuous support from our existing investors. This is an important milestone to reinforce Antengene’s capabilities to bring cutting-edge therapies to help patients with life-threatening diseases in the Asia Pacific regions and around the world.”
Reportedly, the China-based healthcare company has developed a product pipeline of 12 clinical and pre-clinical stage programmes. It has also obtained 7 IND approvals with 10 ongoing cross-regional clinical trials in the Asia Pacific regions in the last three years.